| Irina Lendel, MD | |
|
4301 W Markham St # 587, Little Rock, AR 72205-7101 | |
| (501) 686-8000 | |
| (501) 686-8148 |
| Full Name | Irina Lendel |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 24 Years |
| Location | 4301 W Markham St # 587, Little Rock, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396854352 | NPI | - | NPPES |
| P00447292 | Other | MEDICARE RAILROAD | |
| 3000848 | Other | TN | TN MCARE PIN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Arkansas Heart Hospital, Llc | Little rock, AR | Hospital |
| Chi-st Vincent Infirmary | Little rock, AR | Hospital |
| Baptist Health Medical Center-little Rock | Little rock, AR | Hospital |
| St Vincent Hot Springs | Hot springs, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arkansas Heart Hospital Llc | 6002838653 | 90 |
| Arkansas Heart Hospital Rural Health Services, Llc | 6204004815 | 55 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius issued the following statement today after Anthem Blue Cross announced that they are delaying raising their rates:
News reports indicate COVID-19 vaccines are not getting out soon enough nor in adequate supplies to most regions, but there may be a larger underlying problem than shortages. A University of California, Davis, study found that more than a third of people nationwide are either unlikely or at least hesitant to get a COVID-19 vaccine when it becomes available to them.
Bionovo, Inc., a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that it has entered into definitive agreements to raise approximately $3.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.
Obesity is not only a risk factor for developing knee arthritis. It is also linked to less favorable outcomes after joint replacement surgery. A study at Hospital for Special Surgery (HSS) in New York City finds that bariatric surgery prior to total knee replacement (TKR) is a cost-effective option to improve outcomes.
› Verified 5 days ago
| Entity Name | Arkansas Heart Hospital Rural Health Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548553811 PECOS PAC ID: 6204004815 Enrollment ID: O20110727000090 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius issued the following statement today after Anthem Blue Cross announced that they are delaying raising their rates:
News reports indicate COVID-19 vaccines are not getting out soon enough nor in adequate supplies to most regions, but there may be a larger underlying problem than shortages. A University of California, Davis, study found that more than a third of people nationwide are either unlikely or at least hesitant to get a COVID-19 vaccine when it becomes available to them.
Bionovo, Inc., a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that it has entered into definitive agreements to raise approximately $3.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.
Obesity is not only a risk factor for developing knee arthritis. It is also linked to less favorable outcomes after joint replacement surgery. A study at Hospital for Special Surgery (HSS) in New York City finds that bariatric surgery prior to total knee replacement (TKR) is a cost-effective option to improve outcomes.
› Verified 5 days ago
| Entity Name | Arkansas Heart Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558653212 PECOS PAC ID: 6002838653 Enrollment ID: O20110729000327 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius issued the following statement today after Anthem Blue Cross announced that they are delaying raising their rates:
News reports indicate COVID-19 vaccines are not getting out soon enough nor in adequate supplies to most regions, but there may be a larger underlying problem than shortages. A University of California, Davis, study found that more than a third of people nationwide are either unlikely or at least hesitant to get a COVID-19 vaccine when it becomes available to them.
Bionovo, Inc., a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that it has entered into definitive agreements to raise approximately $3.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.
Obesity is not only a risk factor for developing knee arthritis. It is also linked to less favorable outcomes after joint replacement surgery. A study at Hospital for Special Surgery (HSS) in New York City finds that bariatric surgery prior to total knee replacement (TKR) is a cost-effective option to improve outcomes.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Irina Lendel, MD 4301 W Markham St # 587, Little Rock, AR 72205-7101 Ph: (501) 686-8000 | Irina Lendel, MD 4301 W Markham St # 587, Little Rock, AR 72205-7101 Ph: (501) 686-8000 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius issued the following statement today after Anthem Blue Cross announced that they are delaying raising their rates:
News reports indicate COVID-19 vaccines are not getting out soon enough nor in adequate supplies to most regions, but there may be a larger underlying problem than shortages. A University of California, Davis, study found that more than a third of people nationwide are either unlikely or at least hesitant to get a COVID-19 vaccine when it becomes available to them.
Bionovo, Inc., a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that it has entered into definitive agreements to raise approximately $3.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.
Obesity is not only a risk factor for developing knee arthritis. It is also linked to less favorable outcomes after joint replacement surgery. A study at Hospital for Special Surgery (HSS) in New York City finds that bariatric surgery prior to total knee replacement (TKR) is a cost-effective option to improve outcomes.
› Verified 5 days ago
Lonnie E Harrison, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 7 Shackleford West Blvd, Little Rock, AR 72211 Phone: 501-664-5860 Fax: 501-664-0889 | |
Muthu Veera Kumaran, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 556, Little Rock, AR 72205 Phone: 501-686-6033 Fax: 501-686-8932 | |
Armaghan Yunis Soomro, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1701 S Shackleford Rd, Little Rock, AR 72211 Phone: 501-219-7282 Fax: 201-277-9765 | |
Tanvi Harishbhai Patel, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 508, Little Rock, AR 72205 Phone: 501-686-7105 Fax: 501-526-5906 | |
Gaurav Dhar, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 783, Little Rock, AR 72205 Phone: 501-686-8000 | |
Anthony R Giglia Iii, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 5800 W 10th St, Ste 610 Freeway Medical Center, Little Rock, AR 72204 Phone: 501-661-9393 Fax: 501-663-4795 | |
Brian Bean, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: #2 St Vincent Circle, Little Rock, AR 72205 Phone: 501-552-3592 Fax: 501-552-4129 |